SBIR-STTR Award

The objective of the proposed project is evaluation of two novel non aluminum vaccine adjuvants CpG ODN and AdVaxinulin polysaccharide with intranasal delivery of thermostable live attenuated influenza vaccine LAIV and irradiation inactivation inactivated influenza vaccine Ir IIV powders, The proposal aims to formulate thermostable vaccines in the dry powder format using patented Preservation by Vaporization PBV technology deliver the vaccines intranasally in a ferret model using a low cost respiratory powder delivery deviceand evaluate the protective efficacy and mucosal immunology induced by each of the adjuvant vaccine combinations These studies using influenza as a model vaccine will provide important mechanistic information about inflammatory vsanti inflammatory adjuvants upon intranasal administration while advancing formulations of thermostable adjuvanted respiratory influenza vaccines toward clinical trial and marketThis project seeks to support commercialization of several innovate technologiesnew aluminum free adjuvants with demonstrated safety and efficacyPBV platform technology to enable thermostable biologics for needle free deliveryand an intranasally delivered powder influenza vaccine Outcomes of this study will direct further pre clinical development and commercialization of these promising adjuvants for novel mucosal administration addressing the crucial lack of safe and effective adjuvants for human vaccines